BR112017008212A2 - método de quantificação absoluta de peptídeos de câncer processados naturalmente e restritos por hla - Google Patents

método de quantificação absoluta de peptídeos de câncer processados naturalmente e restritos por hla

Info

Publication number
BR112017008212A2
BR112017008212A2 BR112017008212A BR112017008212A BR112017008212A2 BR 112017008212 A2 BR112017008212 A2 BR 112017008212A2 BR 112017008212 A BR112017008212 A BR 112017008212A BR 112017008212 A BR112017008212 A BR 112017008212A BR 112017008212 A2 BR112017008212 A2 BR 112017008212A2
Authority
BR
Brazil
Prior art keywords
hla
restricted
naturally processed
cancer peptides
quantification method
Prior art date
Application number
BR112017008212A
Other languages
English (en)
Other versions
BR112017008212B1 (pt
Inventor
Leibold Julia
Weinschenk Toni
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of BR112017008212A2 publication Critical patent/BR112017008212A2/pt
Publication of BR112017008212B1 publication Critical patent/BR112017008212B1/pt

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848Methods of protein analysis involving mass spectrometry
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966Animal cells
    • G01N33/56977HLA or MHC typing
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in eptitope analysis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539MHC-molecules, e.g. HLA-molecules
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2458/00Labels used in chemical analysis of biological material
    • G01N2458/15Non-radioactive isotope labels, e.g. for detection by mass spectrometry
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2496/00Reference solutions for assays of biological material
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2560/00Chemical aspects of mass spectrometric analysis of biological material
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2570/00Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)

Abstract

a presente invenção refere-se a um método de quantificação absoluta de peptídeos de câncer processados naturalmente e restritos por hla, isto é, a determinação do número de cópias de peptídeos apresentados em cada célula. a presente invenção pode ser usada tanto para desenvolver tratamentos à base de anticorpos ou vacinas peptídicas como para monitoramento imunológico definido molecularmente, sendo também útil em processos de identificação de novos antígenos peptídicos para estratégias imunoterápicas, tais como vacinas para tal finalidade, terapias à base de anticorpos ou técnicas baseadas em transferência de células t contra o câncer, doenças infecciosas e/ou autoimunes.
BR112017008212-8A 2014-12-30 2015-12-15 Método de quantificação absoluta de pelo menos um peptídeo ligante de mhc em uma célula BR112017008212B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462097994P 2014-12-30 2014-12-30
GB1423361.3 2014-12-30
GBGB1423361.3A GB201423361D0 (en) 2014-12-30 2014-12-30 Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides
US62/097,994 2014-12-30
PCT/EP2015/079873 WO2016107740A1 (en) 2014-12-30 2015-12-15 Method for the absolute quantification of naturally processed hla-restricted cancer peptides

Publications (2)

Publication Number Publication Date
BR112017008212A2 true BR112017008212A2 (pt) 2017-12-26
BR112017008212B1 BR112017008212B1 (pt) 2023-11-28

Family

ID=52471641

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017008212-8A BR112017008212B1 (pt) 2014-12-30 2015-12-15 Método de quantificação absoluta de pelo menos um peptídeo ligante de mhc em uma célula

Country Status (35)

Country Link
US (2) US10545154B2 (pt)
EP (1) EP3241026B1 (pt)
JP (1) JP6735741B2 (pt)
KR (1) KR102336968B1 (pt)
CN (1) CN107003322B (pt)
AU (1) AU2015373584B2 (pt)
BR (1) BR112017008212B1 (pt)
CA (1) CA2972306C (pt)
CL (1) CL2017001071A1 (pt)
CO (1) CO2017004543A2 (pt)
CR (1) CR20170297A (pt)
CY (1) CY1124223T1 (pt)
DK (1) DK3241026T3 (pt)
EA (1) EA036328B1 (pt)
ES (1) ES2871035T3 (pt)
GB (1) GB201423361D0 (pt)
HR (1) HRP20210811T1 (pt)
HU (1) HUE054455T2 (pt)
IL (1) IL250982B (pt)
LT (1) LT3241026T (pt)
MA (2) MA40137B1 (pt)
MD (1) MD3241026T2 (pt)
MX (1) MX2017008722A (pt)
MY (1) MY190199A (pt)
PE (1) PE20171136A1 (pt)
PH (1) PH12017500483A1 (pt)
PL (1) PL3241026T3 (pt)
PT (1) PT3241026T (pt)
RS (1) RS61914B1 (pt)
SG (2) SG11201703841VA (pt)
SI (1) SI3241026T1 (pt)
TW (1) TWI632370B (pt)
UA (1) UA122774C2 (pt)
WO (1) WO2016107740A1 (pt)
ZA (1) ZA201701646B (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201423361D0 (en) * 2014-12-30 2015-02-11 Immatics Biotechnologies Gmbh Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides
TWI755158B (zh) * 2015-03-17 2022-02-11 德商英麥提克生物技術股份有限公司 用於抗胰臟癌與其他癌症的免疫治療的新穎胜肽及胜肽的組合
GB201513921D0 (en) 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
EP4317432A3 (en) 2016-12-08 2024-04-17 Immatics Biotechnologies GmbH T cell receptors with improved pairing
AU2018298884A1 (en) 2017-07-14 2020-02-27 Immatics Biotechnologies Gmbh Improved dual specificity polypeptide molecule
DE102017127984B4 (de) 2017-11-27 2019-12-05 Immatics US, Inc. Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen
JP7470640B2 (ja) * 2018-02-09 2024-04-18 イマティクス ユーエス,アイエヌシー. T細胞を製造する方法
DE102018107224A1 (de) 2018-02-21 2019-08-22 Immatics Biotechnologies Gmbh Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
KR20200027858A (ko) * 2018-09-05 2020-03-13 에스케이하이닉스 주식회사 메모리 컨트롤러 및 이를 포함하는 메모리 시스템
TW202039535A (zh) 2018-12-18 2020-11-01 德商英麥提克生物技術股份有限公司 B*08限制肽和肽組合物抗癌免疫治療和相關方法
US20200297768A1 (en) 2019-03-19 2020-09-24 Immatics US, Inc. Cd28 t cell cultures, compositions, and methods of using thereof
WO2020243134A1 (en) 2019-05-27 2020-12-03 Immatics US, Inc. Viral vectors and their use in adoptive cellular therapy
US20200384028A1 (en) 2019-06-06 2020-12-10 Immatics Biotechnologies Gmbh Sorting with counter selection using sequence similar peptides
US20210032370A1 (en) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Recruiting agent further binding an mhc molecule
DE102019121007A1 (de) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Antigenbindende Proteine, die spezifisch an MAGE-A binden
US20210041454A1 (en) 2019-08-09 2021-02-11 Immatics US, Inc. Methods for peptide mass spectrometry fragmentation prediction
US20210048442A1 (en) 2019-08-13 2021-02-18 Immatics Biotechnologies Gmbh Method for the characterization of peptide:mhc binding polypeptides
MX2022010461A (es) 2020-02-24 2022-12-13 Immatics Us Inc Metodos para expandir linfocitos t para el tratamiento de cancer y neoplasias malignas asociadas.
DE102020106710A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
JP2023527293A (ja) 2020-05-19 2023-06-28 アムジエン・インコーポレーテツド Mageb2結合構築物
TW202227616A (zh) 2020-08-21 2022-07-16 美商英麥提克斯股份有限公司 分離cd8+選擇t細胞的方法
DE102020125457A1 (de) 2020-09-29 2022-03-31 Immatics Biotechnologies Gmbh Amidierte Peptide und ihre deamidierten Gegenstücke, die durch HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
TW202241938A (zh) 2020-12-31 2022-11-01 美商英麥提克斯股份有限公司 Cd8多肽、組合物及其使用方法
AU2022269828A1 (en) 2021-05-05 2023-11-23 Immatics Biotechnologies Gmbh Bma031 antigen binding polypeptides
EP4334361A1 (en) 2021-05-05 2024-03-13 Immatics Biotechnologies GmbH Antigen binding proteins specifically binding prame
EP4113120A1 (en) 2021-06-28 2023-01-04 Immatics Biotechnologies GmbH Method of characterizing the binding characteristics between a peptide of interest and mhc molecules
US20230024554A1 (en) 2021-06-28 2023-01-26 Immatics Biotechnologies Gmbh Method of characterizing the binding characteristics between a peptide of interest and mhc molecules
US20230057987A1 (en) 2021-07-27 2023-02-23 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding ct45
WO2023025851A1 (en) 2021-08-24 2023-03-02 Immatics US, Inc. Selection of immune cells using peptide mhc complexes generated by conditional ligand exchange
US20230089392A1 (en) 2021-09-20 2023-03-23 Immatics US, Inc. Monocyte depletion of t cells populations for t-cell therapy
US20230190805A1 (en) 2021-10-06 2023-06-22 Immatics Biotechnologies Gmbh Methods of identifying metastatic lesions in a patient and treating thereof
WO2023081925A1 (en) 2021-11-08 2023-05-11 Immatics Biotechnologies Gmbh Adoptive cell therapy combination treatment and compositions thereof
WO2023212691A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. DOMINANT NEGATIVE TGFβ RECEPTOR POLYPEPTIDES, CD8 POLYPEPTIDES, CELLS, COMPOSITIONS, AND METHODS OF USING THEREOF
US20230348548A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof
WO2023212655A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof
US20230355678A1 (en) 2022-05-05 2023-11-09 Immatics US, Inc. Methods for improving t cell efficacy

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4290003B2 (ja) 2001-09-14 2009-07-01 エレクトロフォレティクス リミテッド 質量標識体
DE10225139A1 (de) 2002-05-29 2004-02-26 Immatics Biotechnologies Gmbh Verfahren zur Identifizierung von immunreaktiven Peptiden
US20050221350A1 (en) * 2002-05-29 2005-10-06 Toni Weinschenk Method for identifying immunoreactive peptides
US6644103B1 (en) 2002-10-24 2003-11-11 Simmonds Precision Products, Inc. Method and apparatus for detecting a dry/wet state of a thermistor bead
WO2004042401A1 (ja) * 2002-11-08 2004-05-21 Hiroshi Takahashi 癌細胞の検査方法及びそのための試薬
JP2007519910A (ja) 2004-01-28 2007-07-19 イマティクス バイオテクノロジーズ ゲーエムベーハー 腫瘍関連ペプチドの同定および定量方法
JP2008043332A (ja) * 2006-08-17 2008-02-28 Panomics Inc 組織スライドからの核酸定量
ES2536465T3 (es) * 2008-10-01 2015-05-25 Immatics Biotechnologies Gmbh Composición de péptidos tumor-asociados y relacionados con la vacuna contra el cáncer para el tratamiento de glioblastoma (GBM) y otros cánceres
GB201004551D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201006360D0 (en) * 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
WO2012140429A2 (en) 2011-04-15 2012-10-18 Micromass Uk Limited Method and apparatus for the analysis of biological samples
WO2012178030A2 (en) 2011-06-24 2012-12-27 Applied Isotope Technologies, Inc. Accurate measurement of glutathione for disease diagnosis and drug metabolite screening
US10077171B2 (en) * 2012-10-17 2018-09-18 Grant C. Chustz Safety barrier for vehicles and cranes
GB201423361D0 (en) * 2014-12-30 2015-02-11 Immatics Biotechnologies Gmbh Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides
DE102016115246C5 (de) * 2016-08-17 2018-12-20 Immatics Biotechnologies Gmbh Neue t-zellrezeptoren und deren verwendung in immuntherapie
IL274505B2 (en) * 2017-11-06 2024-04-01 Immatics Biotechnologies Gmbh Transgenic T-cell receptors and immunotherapy using them

Also Published As

Publication number Publication date
ZA201701646B (en) 2018-05-30
LT3241026T (lt) 2021-05-25
KR20170099914A (ko) 2017-09-01
EA036328B1 (ru) 2020-10-27
SG11201703841VA (en) 2017-07-28
MA40137A1 (fr) 2018-03-30
MX2017008722A (es) 2017-10-18
CA2972306C (en) 2021-02-16
GB201423361D0 (en) 2015-02-11
PE20171136A1 (es) 2017-08-09
TW201631320A (zh) 2016-09-01
US20200103408A1 (en) 2020-04-02
SG10201913988XA (en) 2020-03-30
EP3241026B1 (en) 2021-04-14
HUE054455T2 (hu) 2021-09-28
HRP20210811T1 (hr) 2021-09-03
CR20170297A (es) 2017-10-19
WO2016107740A1 (en) 2016-07-07
CA2972306A1 (en) 2016-07-07
EP3241026A1 (en) 2017-11-08
CO2017004543A2 (es) 2017-09-29
TWI632370B (zh) 2018-08-11
PH12017500483A1 (en) 2017-08-07
AU2015373584A1 (en) 2017-04-20
RS61914B1 (sr) 2021-06-30
BR112017008212B1 (pt) 2023-11-28
MA40137B1 (fr) 2019-05-31
CY1124223T1 (el) 2022-05-27
MA41287A (fr) 2017-11-08
MA41287B1 (fr) 2021-07-29
KR102336968B1 (ko) 2021-12-08
PT3241026T (pt) 2021-05-25
IL250982A0 (en) 2017-04-30
ES2871035T3 (es) 2021-10-28
DK3241026T3 (da) 2021-05-10
JP2018500004A (ja) 2018-01-11
CN107003322A (zh) 2017-08-01
US20160187351A1 (en) 2016-06-30
MY190199A (en) 2022-04-04
US11988669B2 (en) 2024-05-21
PL3241026T3 (pl) 2021-10-25
CN107003322B (zh) 2019-08-30
IL250982B (en) 2020-08-31
US10545154B2 (en) 2020-01-28
SI3241026T1 (sl) 2021-08-31
EA201791148A1 (ru) 2017-11-30
JP6735741B2 (ja) 2020-08-05
UA122774C2 (uk) 2021-01-06
MD3241026T2 (ro) 2021-07-31
CL2017001071A1 (es) 2017-12-22
AU2015373584B2 (en) 2022-02-24

Similar Documents

Publication Publication Date Title
BR112017008212A2 (pt) método de quantificação absoluta de peptídeos de câncer processados naturalmente e restritos por hla
CY1123563T1 (el) Ανοσογονικα wt-1 πεπτιδια και μεθοδοι χρησης αυτων
CY1121893T1 (el) Μορια αντισωματος κατα της τιμ-3 και χρησεις αυτων
CY1121962T1 (el) Υποδοχεις τ κυτταρου
CL2020000192A1 (es) Anticuerpos anti-cd8 y usos de estos.
CY1121743T1 (el) Μονοκλωνικα αντισωματα προς χρηση στη διαγνωση και θεραπεια απο καρκινους και αυτοανοση νοσο
CO2017000300A2 (es) Moléculas con especificidad para cd45 y cd79
CO2017006808A2 (es) Receptores de antígenos quiméricos de bcma
MX2017000116A (es) Moleculas basadas en il-15 y metodos para su uso.
BR112018006251A2 (pt) anticorpos antagonistas que se ligam especificamente a cd40 humano e métodos de uso
AR105433A1 (es) Métodos para mejorar la eficacia y expansión de las células inmunes
CO2017004932A2 (es) Métodos para seleccionar una línea de células t y donador de la misma para terapia celular adoptiva
BR112018012344A2 (pt) anticorpos que se ligam especificamente a hla-dr e seus usos
MX2013007918A (es) Peptidos inmunogenicos monomericos y multimericos.
ZA202206809B (en) Hiv vaccines comprising one or more population episensus antigens
MX2022006561A (es) Anticuerpos anti-influenza b neutralizantes y usos de los mismos.
PH12017500722A1 (en) Antibodies that potently neutralize rabies virus and other lyssaviruses and uses thereof
PH12015502713A1 (en) Method for upregulating antigen expression
BR112018002319A2 (pt) anticorpos anti-cd154 e métodos de uso dos mesmos
BR112016016737A2 (pt) Peptídeos, dispositivos e métodos para detecção de anticorpos contra anaplasma
BR112017017878A2 (pt) método, suporte e kit de coleta de ácido(s) nucleico(s)
MX2018008198A (es) Metodos para caracterizar composiciones que comprenden antigenos de cacahuate.
WO2015143194A3 (en) Immunogenetic restriction on elicitation of antibodies
MX2017011972A (es) Metodo de tratamiento novedoso.
BR112016020043A2 (pt) composições e métodos para a identificação de malignidades de linfócitos b responsivas à terapia de depleção de linfócitos b

Legal Events

Date Code Title Description
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/12/2015, OBSERVADAS AS CONDICOES LEGAIS